This company listing is no longer active
Centessa Pharmaceuticals (0ACX) Stock Overview
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0ACX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.45 |
| 52 Week High | US$41.80 |
| 52 Week Low | US$12.86 |
| Beta | 1.12 |
| 1 Month Change | 1.68% |
| 3 Month Change | 40.12% |
| 1 Year Change | 214.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 333.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ACX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.3% | 0.2% | 0.3% |
| 1Y | 214.6% | 2.8% | 16.0% |
Return vs Industry: 0ACX exceeded the UK Biotechs industry which returned 24.7% over the past year.
Return vs Market: 0ACX exceeded the UK Market which returned 18.7% over the past year.
Price Volatility
| 0ACX volatility | |
|---|---|
| 0ACX Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0ACX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0ACX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 129 | Mario Accardi | centessa.com |
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
Centessa Pharmaceuticals plc Fundamentals Summary
| 0ACX fundamental statistics | |
|---|---|
| Market cap | US$6.27b |
| Earnings (TTM) | -US$250.64m |
| Revenue (TTM) | n/a |
Is 0ACX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ACX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$250.64m |
| Earnings | -US$250.64m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 22.7% |
How did 0ACX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 15:36 |
| End of Day Share Price | 2026/06/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Centessa Pharmaceuticals plc is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Umer Raffat | Evercore ISI |
| Andrea Newkirk | Goldman Sachs |